clindamycin phosphate vaginal cream 2% — Competitive Intelligence Brief

clindamycin phosphate vaginal cream 2% (clindamycin phosphate vaginal cream 2%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lincosamide antibiotic. Area: Infectious Disease / Gynecology.

phase 3 Lincosamide antibiotic Bacterial 50S ribosomal subunit Infectious Disease / Gynecology Small molecule

Target snapshot

clindamycin phosphate vaginal cream 2% (clindamycin phosphate vaginal cream 2%) — Actavis Inc.. Clindamycin phosphate is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby killing or inhibiting the growth of anaerobic bacteria and some gram-positive organisms responsible for bacterial vaginosis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
clindamycin phosphate vaginal cream 2% TARGET	clindamycin phosphate vaginal cream 2%	Actavis Inc.	phase 3	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Clarithromycin (ST14)	Clarithromycin (ST14)	National Taiwan University Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1 gram IV	Azithromycin 1 gram IV	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
linezolid (Zyvox)	linezolid (Zyvox)	Pfizer	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithropycin according to symptoms	Azithropycin according to symptoms	University Hospital, Montpellier	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit (23S rRNA)
Azithromycin Oral Product	Azithromycin Oral Product	Thomas Jefferson University	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Clindamycin Topical Gel 1%	Clindamycin Topical Gel 1%	Jinnah Postgraduate Medical Centre	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lincosamide antibiotic class)

1. GlaxoSmithKline · 2 drugs in this class
2. Balmoral Medical company · 1 drug in this class
3. Generic (originally Upjohn/Pfizer) · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Janssen-Cilag, S.A. · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Oral and Maxillofacial Surgery Clinic, Poland · 1 drug in this class
8. Stiefel, a GSK Company · 1 drug in this class
9. Actavis Inc. · 1 drug in this class
10. University of Toronto · 1 drug in this class